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Pancreatic cysts suspected to be branch duct intraductal papillary 
mucinous neoplasm without concerning features have low risk for 
development of pancreatic cancer
Robert D. Lawsona, Gordon C. Huntb, Andrew Q. Giapc, Mary L. Krinskyd, Jeff  Slezake, 
Raymond S. Tangf, Ingrid Gonzalezg, Wilson T. Kwongh, Syed A. Fehmih, Thomas J. Savidesh
Naval Medical Center, San Diego, CA; Kaiser Permanente, San Diego; Kaiser Permanente, Anaheim, CA; Veterans 
Aff airs Medical Center, La Jolla, CA; Kaiser Permanente, Pasadena, CA; Institute of Digestive Disease, Th e Chinese 
University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong; Digestive Health Specialists, NC; University of 
California, La Jolla, CA
Background Th e risk of developing pancreatic cancer is uncertain in patients with clinically 
suspected branch duct intraductal papillary mucinous neoplasm (BD-IPMN) based on the “high-
risk stigmata” or “worrisome features” criteria proposed in the 2012 international consensus 
guidelines (“Fukuoka criteria”).
Methods Retrospective case series involving patients referred for endoscopic ultrasound (EUS) 
of indeterminate pancreatic cysts with clinical and EUS features consistent with BD-IPMN. Rates 
of pancreatic cancer occurring at any location in the pancreas were compared between groups of 
patients with one or more Fukuoka criteria (“Highest-Risk Group”, HRG) and those without these 
criteria (“Lowest-Risk Group”, LRG).
Results Aft er exclusions, 661 patients comprised the fi nal cohort (250 HRG and 411 LRG patients), 
62% female with an average age of 67 years and 4 years of follow up. Pancreatic cancer, primarily 
adenocarcinoma, occurred in 60 patients (59 HRG, 1 LRG). Prevalent cancers diagnosed during 
EUS, immediate surgery, or fi rst year of follow up were found in 48/661  (7.3%) of cohort and 
exclusively in HRG (33/77, 42.3%). Using Kaplan-Meier method, the cumulative incidence of 
cancer at 7 years was 28% in HRG and 1.2% in LRG patients (P<0.001).
Conclusions Th is study supports using Fukuoka criteria to stratify the immediate and long-term 
risks of pancreatic cancer in presumptive BD-IPMN. Th e risk of pancreatic cancer was highest 
during the fi rst year and occurred exclusively in those with “high-risk stigmata” or “worrisome 
features” criteria. Aft er the fi rst year all BD-IPMN continued to have a low but persistent 
cancer risk.
Keywords Pancreatic cyst, pancreatic cancer, natural history, endosonography, intraductal 
papillary mucinous neoplasm
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Introduction
Pancreatic cancer is usually discovered at advanced stage 
and there are no screening or surveillance strategies proven to 
reduce risk. Pancreatic cysts have been targeted for intervention 
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since mucin-producing cysts are associated with a risk of 
progression to adenocarcinoma over time. Th ough pancreatic 
cysts are easily identifi ed on cross-sectional imaging, most 
types pose no risk of malignant degeneration. With trending 
use and improvements in imaging, incidental pancreatic cysts 
have been increasingly detected, occurring in 2.4-14.4% of the 
general population [1-3]. Th e minority of these cysts are easily 
and accurately distinguished using clinical and radiographic 
features such as main duct intraductal papillary mucinous 
neoplasms (MD-IPMN) and high-risk (≥3 cm in size) mucinous 
cystic neoplasms (MCN). However,  computed tomography 
(CT) and magnetic resonance imaging/magnetic resonance 
cholangiopancreatography (MRI/MRCP) perform poorly in 
discerning cyst type for the majority of cysts, with accuracy 
of diagnosis <50% [4]. Many are presumably neoplastic cysts 
such as branch duct (BD)-IPMN or small MCN whose natural 
history and risk for progression to adenocarcinoma are poorly 
understood [5,6]. Resection is reserved for symptomatic 
or probable malignant cysts with features as suggested per 
Fukuoka criteria and the 2015 AGA guidelines on diagnosis and 
management of asymptomatic neoplastic pancreatic cysts [7]. 
Surgical resection of pancreatic cysts carries a morbidity of 35% 
and mortality of 1% [8-13]. Th us, non-operative management 
in most cases is reasonable as transformation of pancreatic cysts 
into adenocarcinoma appears to be a rare event (33.2 events 
per 100,000) [14]. Th e challenge is discerning BD-IPMN with 
highest malignant potential that warrant operative management 
from those that can be safely entered into a surveillance 
program, thereby minimizing risks to this patient population.
In 2006 international consensus guidelines for the 
management of pancreatic BD-IPMN and MCN were released 
by the International Association of Pancreatology (IAP) [15] 
and in 2012 were updated [16]. Th e most notable changes in 
the revised Fukuoka guidelines were refi nements in criteria 
used to stratify the malignant potential of BD-IPMN (“Fukuoka 
criteria”), and de-emphasis of cyst size ≥30  mm solely as an 
indication for surgery. Th e Fukuoka criteria are separated 
into “high-risk stigmata” [obstructive jaundice with cystic 
lesion located in the head of the pancreas, cyst containing an 
enhancing solid component, and main pancreatic duct (PD) 
diameter ≥10 mm] and “worrisome features” (pancreatitis, cyst 
size ≥30 mm, thickened/enhancing cyst walls, PD size 5-9 mm, 
cyst with non-enhancing mural nodule, abrupt change in caliber 
of PD with distal pancreatic atrophy, and lymphadenopathy). 
Consideration of immediate resection is recommended for 
surgically fi t patients with “high-risk stigmata”, “worrisome 
features” and concerning endoscopic ultrasound (EUS) fi ndings 
(defi nite mural nodule, PD abnormalities and fi ne-needle 
aspiration (FNA) cytology with either high-grade dysplasia 
or malignant cell) or otherwise benign-appearing cyst with 
high-grade epithelial atypia. In the absence of Fukuoka criteria 
and/or high-risk EUS-FNA features, BD-IPMN are thought 
to confer low risk for malignancy and are suitable for non-
operative management and surveillance.
Th e aim of this study was to evaluate the performance of 
Fukuoka criteria in stratifying risk of pancreatic cancer of 
clinically suspected BD-IPMN, and identifying low-risk cysts that 
can be safely managed non-operatively following EUS evaluation.
Patients and methods
Th is is a retrospective study involving consecutive 
patients who underwent pancreaticobiliary EUS evaluation 
of indeterminate pancreatic cysts between December 2000 
and July 2012 at four referral centers in the same geographic 
region. Th e primary end points of this study were development 
of pancreatic cancer and survival in the HRG and LRG. Each 
center obtained Institutional Review Board approval. Included 
in the study were patients ≥18  years of age referred for EUS 
evaluation of one or more newly discovered pancreatic cysts 
with EUS features consistent with BD-IPMN. Patients 
were referred by their primary care provider, surgeon, or 
gastroenterologist aft er discovery of one or more pancreatic 
cysts on CT, MRI or transcutaneous ultrasound. Aft er EUS 
evaluation, the management of each patient was individualized 
based upon cyst characteristics, patient age and comorbidity. 
EUS procedure reports and electronic medical records (EMR) 
were reviewed for patient demographics and medical history, 
associated symptoms at time of referral, and EUS fi ndings 
(i.e.  Fukuoka criteria, location in pancreas, number, size of 
largest cyst if multifocal or of conglomeration of abutting 
cysts, and morphology), FNA cytology, cyst fl uid analyses 
and clinical follow up. Patients or close family members 
were contacted by telephone or online death registries were 
reviewed if follow-up information was not obtainable through 
review of the EMR. Diagnosis of pancreatic malignancy was 
based on FNA cytology, surgical pathology, or surveillance CT 
or MRI showing an obvious, locally invasive pancreatic mass. 
When patient was deceased, telephone interview of a close 
family member was utilized to confi rm pancreatic malignancy. 
Prevalent cancers were defi ned as those that were diagnosed 
at the time of EUS-FNA, early surgery or during fi rst year 
of follow up. Date and cause of death were determined by 
reviewing patients’ electronic medical records, contacting 
family members, or from online registries.
A single unifocal, septated or “honeycombed” pancreatic 
cyst was classifi ed as “unilocular”, whereas multiple, discrete 
cysts were classifi ed as either “abutting” (including oligocystic 
and multilobular cysts) or “separate” depending on whether or 
not cysts were contiguous. Th e size of the largest discrete cyst 
or conglomeration of abutting cysts in each patient was used 
for analyses. Pancreatic cysts were categorized into one of six 
suspected cyst types using clinical and EUS features as follows. 
MD-IPMN  -  isolated segmental or diff use dilation of PD 
≥5 mm. MCN - unilocular cyst ≥30 mm in size located within 
the body or tail of female patients. Serous cystic neoplasm 
(SCN)  -  unilocular cyst with honeycomb appearance with 
normal caliber PD. BD-IPMN  -  unilocular cyst <30  mm in 
size or multifocal cysts located anywhere within the pancreas 
associated with normal PD (i.e. <5 mm). Suspected BD-IPMNs 
were classifi ed as main duct or mixed-IPMN when there was 
an associated dilated PD (i.e. ≥5 mm). Cysts were classifi ed as 
suspected pseudocysts if discovered aft er an episode of acute 
pancreatitis or located predominantly outside the pancreas 
parenchyma. EUS documentation of clear communication 
between cysts and the PD was reported at the discretion of 
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each endosonographer, and if present these were considered 
BD-IPMN, but if no mention in the report of whether the cyst 
communicated with the PD then the cysts were still considered 
as suspected BD-IPMN if were multiple cysts and did not 
have an appearance or clinical characteristics consistent with 
other types of pancreatic cystic lesion. FNA was not routinely 
performed but rather performed at the discretion of each 
endoscopist, thus neither cytology nor carcinoembryonic 
antigen (CEA) was used in this study to discern cyst types. 
All sites used rapid on-site cytological evaluation of FNA 
samples. DNA and molecular analysis was not employed for 
any patients.
Following chart review patients were excluded if: cysts 
were not consistent with BD-IPMN, patient had history of 
pancreatic cancer, chronic pancreatitis (imaging demonstrating 
calcifi cations or history or recurrent episodes of pancreatitis), 
suspected pseudocyst (prior history of pancreatitis with new 
pancreatic cyst) or von Hippel-Lindau disease; or, patient did 
not have at least 1 year of clinical follow up in the absence of a 
diagnosis of pancreatic cancer, cyst resection, or death.
Data management and statistical analyses
Data were entered into a password protected de-identifi ed 
database. Patients were divided into two groups, “Highest-
Risk Group” (HRG) and “Lowest-Risk Group” (LRG), based 
the presence of Fukuoka criteria for analysis [16]. Th e HRG 
consisted of BD-IPMN with at least one Fukuoka criterion 
(obstructive jaundice associated with cyst in head of pancreas, 
presence of a solid mass component or mural nodule within 
cyst, PD size ≥5 mm, cyst size ≥30 mm, abrupt change in caliber 
of PD with distal pancreatic atrophy, lymphadenopathy). Th e 
remaining patients with benign-appearing cysts without any 
Fukuoka criteria comprised the LRG.
Follow-up interval for each patient was calculated as the time 
between EUS examination and diagnosis of cancer, surgery, the 
most recent patient contact or death. Associations of individual 
factors with risk groups were tested using either the chi-square 
test or the Wilcoxon rank-sum test. Th e Kaplan-Meier method 
with the log-rank test was used to compare the incidence of 
pancreatic cancer. Patients who underwent surgery or died 
without a cancer diagnosis were censored; however, follow-up 
information on clinical outcomes of pancreatic cancer and/or 
death following surgery was obtained for each patient.
Results
A total of 894  patients underwent EUS evaluation of one 
or more pancreatic cysts identifi ed on CT or MRI during 
the study period (Fig.  1). Of this number 233  patients were 
excluded for the following suspected diagnoses: 16 MD-IMPN; 
29 MCN; 52 SCN; 40 chronic pancreatitis; 35 pseudocyst; 3 
history of pancreatic cancer; 1 with von Hippel-Lindau. 57 were 
excluded for inadequate follow up. Following these exclusions 
661 patients comprised the cohort including 218 patients from 
Kaiser Permanente, Anaheim Medical Center, California; 
148  patients from Kaiser Permanente, San Diego Medical 
Center/Kaiser Foundation Hospital, California; 235  patients 
from the University of California, San Diego, California; 
and 60  patients from the Veterans Administration Medical 
Center, La Jolla, California. Females comprised 55.8%; average 
age was 67.4  years; and pancreatic cysts were predominantly 
asymptomatic (67%). Compared to the LRG, patients in the 
HRG were more oft en male (53.6% vs 38.4%, P=0.0001), older 
(68.7  years vs. 66.5  years, P=0.0051), followed for a shorter 
period of time (3.7 years vs. 4.1 years, P= 0.0013), more oft en 
symptomatic (46.4% vs. 24.8%, P<0.0001) and more likely 
Figure 1 Patient screening, exclusion, and group assignment
BD-IPMN, branch duct-intraductal papillary mucinous neoplasm; EUS, endoscopic ultrasound; HRG, highest-risk group; IPMN, intraductal papillary 
mucinous neoplasm; LRG, lowest-risk group
Patients who underwent EUS evaluation
of one or more pancreatic cysts (894)
Excluded (233)
 Main duct IPMN (16, 7%)
 Mucinous cystic neoplasm (29, 12%)
 Serous cystic neoplasm (52, 22%)
 Inadequate follow up (57, 24%)
 Chronic pancreatitis (40, 17%)
 Pseudocyst (35, 15%)
 History of pancreatic cancer (3, <1%)
 History of Von Hippel-Lindau (1, <1%)
Presumptive BD-IPMN (661)
Highest-Risk Group, HRG (250)
“High-risk stigmata” (77)
“worrisome features” (173)
Lowest-Risk Group, LRG (411)
Malignant cytology and/or
Immediate resection (32)
Malignant cytology and/or
Immediate resection (7)
Follow up (218) Follow up (404)
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to undergo surgical resection (14.4% vs. 3.5%, P=0.0001). 
Th e cohort was followed for an average of 3.8 years, ranging 
between 3 days (patients diagnosed with pancreatic cancer at 
time of EUS) to 12 years.
EUS fi ndings
Overall, 250 patients in the cohort (37.8%) had suspected 
BD-IPMN associated with one or more Fukuoka criteria 
and were assigned to the HRG (Fig.  1), leaving 411  (62.2%) 
suspected BD-IPMN that were assigned to the LRG. Of the 
250 assigned to the HRG, 95  (38%) had multiple criteria, 
173  (69.2%) “worrisome features” and 77  (30.8%) “high-risk 
stigmata”, most commonly solid component (54) or a mural 
nodule (25) (Table 1).
Cyst characteristics are summarized in Table  2. Mixed-
IPMN comprised 31% of cysts in the HRG. Compared to 
the cysts in the LRG, those in the HRG were larger in size 
(28.8 mm vs. 15.2 mm, P<0.0001), more frequently located in 
the head of the pancreas (60% vs. 39%, P<0.0001), and more 
oft en occurring as multifocal or as multiple abutting cysts 
rather than as unilocular cysts (52.4% vs. 38.7%, P<0.0001).
FNA
FNA was performed in 163  patients in the HRG (65.2%) 
and 139 in the LRG (33.8%) (P<0.0001). Malignant cytology 
was identifi ed in 30/164  (18.3%) aspirates in the HRG and 
none in the LRG (P<0.0001) (Table 3). Most aspirates with 
malignant cytology (27/30, 90%) and the single aspirate with 
HGD cytology were from cysts with “high-risk stigmata”. CEA 
was obtained in 19  patients who subsequently underwent 
resection during follow up.
Immediate surgery
Within 3  months of EUS exam 34  patients underwent 
surgical resection, 27 from the HRG (10.4%). Th is includes 
16/77  (20.7%) of those with “high-risk stigmata” and 
11/173 (6.4%) of those with only “worrisome features”. Overall 
pathology was malignant in 12  patients, 8 with cysts with 
“high-risk stigmata” and 3 with “worrisome features”. Out 
of the 30  patients who had malignant cytology on FNA, 6 
proceeded to surgery (20%) and in one case surgical pathology 
was non-invasive IPMN. In the LRG 7/411 (1.7%) proceeded 
to surgery within 3 months and pathology was benign.
Follow up
Of the 30  patients with malignant cytology on EUS-
FNA 25 died during follow up (83.3%), 15 within the fi rst 
year (median time to death, 9  months, range 11  days to 
102  months). Cause of death was reported in the EMR for 
10 patients, 9 as complications of metastatic cancer and 1 as 
end-stage Parkinson’s disease. Patients who had malignant 
cytology and were alive during follow up included 3 who did 
not undergo surgery (2 neuroendocrine tumor, 1 diff use large 
B cell lymphoma) and 2 with adenocarcinoma on cytology who 
proceeded to Whipple resection within 2 months (pathology, 
1 pT1N0 adenocarcinoma and 1 IPMN).
Table 1 Th e absolute and relative frequency of occurrence of each 
Fukuoka criterium*
N (% HRG)
“High-risk stigmata” 77 (30.8)
Solid component 53 (21)
Main pancreatic duct diameter ≥10 mm 12 (5)
Jaundice with cyst in head of pancreas 13 (5)
Defi nite mural nodule 25 (10)
“Worrisome features” 173 (69.2)
Pancreatitis 14 (6)
Main pancreatic duct diameter 5-9 mm 66 (27)
Cyst size ≥30 mm 175 (69)
Lymphadenopathy 3 (1.2)
Abrupt change in caliber of pancreatic 
duct with distal pancreatic atrophy
0
*38% of patients had 2 or more criteria.
HRG, highest-risk group; mm, millimeters
Table 2 Comparison between the highest-risk and lowest-risk groups 
of the absolute and relative number of presumptive cyst types, mean 
maximal cyst size, location of dominant cyst within the pancreas, and 
cyst morphology
HRG (N=250) LRG (N=411) P-value
Presumptive cyst type, 
N (%)
Branch duct IPMN 172 (69) 411 (100)
Mixed IPMN 78 (31) 0
Cyst size 
(maximum dimension)
Mean+SD 28.8±15.7 mm 15.2±6 mm <0.0001
Range 5-130 mm 3-29 mm
Location, N (%) <0.0001
Head/neck 149 (60) 159 (39)
Body/tail 101 (40) 252 (61)
Morphology, (%) <0.0001
Single (unilocular) cyst 121 (48) 254 (62)
Multiple, separate cysts 64 (26) 104 (25)
Multiple, abutting cysts 59 (24) 46 (12)
Both separate and 
abutting cysts
6 (2.4) 7 (1.7)
FNA, fine-needle aspiration; HRG, highest-risk group; IPMN, intraductal 
papillary mucinous neoplasm; LRG, lowest-risk group; mm, millimeters 
N, number; P value, probability-value; SD, standard deviation
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Th e remaining 622  patients (218 in HRG and 404 in 
LRG) who had neither malignant cytology on EUS-FNA 
nor resection within 3  months had an average follow up of 
49.5 months (range 10 days to 132 months).
Development of pancreatic cancer
During the fi rst year of follow up pancreatic cancer occurred 
in an additional 10  patients, 8  patients with “worrisome 
features” and 2 with “high-risk stigmata” based upon repeat 
EUS-FNA (5), surgery (1), imaging (2) and interview (1) 
(Table 5). Aft er the fi rst year of follow up 12 additional patients 
developed pancreatic cancer, 11 in the HRG (8 with “worrisome 
features” on index EUS and 3 with “high-risk stigmata” on 
index EUS) and 1 in the LRG based upon repeat FNA (3), 
surgery (4), imaging (2) and interview (3). Th e 1  patient in 
the LRG who developed pancreatic cancer was a female who 
initially underwent EUS at age of 77 for a unilocular 26 mm cyst 
in the pancreas neck with pathology revealing BD-IPMN. Over 
years of follow up multiple cysts accumulated throughout her 
entire pancreas consistent with multifocal BD-IPMN. At 6 years 
aft er presentation, a mass formed in the head of the pancreas, 
confi rmed to be adenocarcinoma on EUS-FNA cytology.
Th ere were 60 cases of pancreatic cancer (59 in HRG and 
1 in LRG), 48 of which (80%) were diagnosed at the time of 
index EUS, immediate surgery or within fi rst year of follow-up 
(Table 5). Th ese prevalent cancers were diagnosed in 6.4% of the 
entire cohort, 19.2% of the HRG (42.8% of those with “high-risk 
stigmata” and 8.7% of those with “worrisome features”) and 0% 
of those in the LRG. Based upon Kaplan-Meier estimates the 
cumulative incidence of pancreatic cancer aft er 7 years of follow 
up was 28% in the HRG and 1.2% in the LRG (P<0.001) (Fig. 2).
Discussion
Th is multicenter study of 661  patients with an average 
of nearly 4  years follow up showed that, collectively, the 
Fukuoka criteria perform exceptionally well in discriminating 
presumptive high-risk BD-IPMN from those posing minimal 
risk or even no risk (such as when patients die from cause other 
than pancreatic disease). Clinically suspected BD-IPMN with 
one or more Fukuoka criteria were much more likely to harbor 
or develop pancreatic cancer compared to those without these 
features. A total of 59 pancreatic malignancies occurred in the 
group of 250 patients with at least one Fukuoka criterion. Th is 
corresponds to a 28% cumulative risk over a 7-year period of 
follow up using Kaplan-Meier analysis. Th ere was only one 
case of pancreatic cancer in the group of 411  patients with 
benign-appearing lesions (1.2% cumulative risk over 7-year 
period). Th ese fi ndings support the use of Fukuoka criteria to 
risk stratify clinically suspected BD-IPMN, as recommended 
in the 2012 revised international consensus guidelines [16].
Most pancreatic malignancies (80%) were found at the 
time of index EUS, immediate surgery or during the fi rst year 
of follow up. Th is emphasizes the importance of a thorough 
evaluation of indeterminate pancreatic cysts at time of 
cyst diagnosis and during the fi rst year of follow up. Th ese 
prevalent cancers were found in 7.3% of the cohort which is 
Table 3 Frequency of fi ne-needle aspiration and cytology 
performance and the associated cytology interpretations within the 
highest-risk and lowest-risk groups
FNA 
N  (%)
Malignant 
cytology 
N  (%)
Cytology 
interpretation  (N)
Highest-risk group
“High-risk stigmata” 61 (79) 49 (80) Adenocarcinoma (24), 
NET (3), 
IPMN+HGD (1), 
Atypical cells (8), 
Mucin (1), Benign 
cells (10), ND (3)
“Worrisome features” 103 (60) 65 (63) Adenocarcinoma (2), 
DLBCL (1), Benign 
cells (41), Atypical 
cells (9), Mucin (1), 
ND (11)
Lowest-risk group 139 (34) 63 (45) Benign cells (51), 
Atypical cells (7), 
Mucin (1), ND (4)
DLBCL, diffuse large B cell lymphoma; FNA, fine-needle aspiration; 
IPMN, intraductal papillary mucinous neoplasm; HGD, high-grade dysplasia; 
N, number; NET, neuroendocrine tumor; ND, non-diagnostic
Table 4 Frequency of pancreatic surgery and associated pathology in 
the highest-risk and lowest-risk groups
N Pathology  (N)
Surgery within 3 months
Highest-risk group
“High-risk stigmata” 16 Adenocarcinoma (6), IPMN/
invasive adenocarcinoma (2), MCN/
invasive adenocarcinoma (1), 
Cystadenocarcinoma (1), IPMN (4), 
SCN (1), ERC (1)
“Worrisome features” 11 Adenocarcinoma (2), MD 
IPMN+invasive adenocarcinoma, 
IPMN+HGD (1)
IPMN (3), MCN (1), pseudocyst (1), 
unavailable (1)
Lowest-risk group 7 MCN (3), IPMN (2), SPT (1), ERC (1)
Surgery aft er 3 months
Highest-risk group
“High-risk stigmata” 2 NET (1), IPMN (1)
“Worrisome features” 7 Adenocarcinoma (2), IPMN/
invasive adenocarcinoma (1), 
Leiomyosarcoma (1)
IPMN (1), SCN (1), unavailable (1)
Lowest-risk group 8 IPMN (2), MCN (2), SCN (1), 
ERC (2), unavailable (1)
IPMN, intraductal papillary mucinous neoplasm; ERC, epithelial retention 
cyst; HGD, high grade dysplasia; MCN, mucinous cystic neoplasm; N, number; 
NET, neuroendocrine tumor; SCN, serous cystic neoplasm; SPT,  solid 
pseudopapillary tumor
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much lower than the estimate of 25.5% derived from surgical 
data of resected BD-IPMN [5] and likely refl ects diff erences 
in patient populations and referral patterns. Furthermore, 
prevalent cancers occurred exclusively in the HRG and were 
more frequent in patients with “high-risk stigmata” compared 
to those with only “worrisome features” (42.3% vs. 8.7%). Th is 
fi nding concurs with the surgical literature that has consistently 
shown higher rates of pancreatic cancer in BD-IPMN with 
high-risk features compared to those without [17-28]. Th ese 
fi ndings support the relative weighting of importance of 
Fukuoka criteria and the recommendation for consideration 
of immediate surgical resection for cysts with “high-risk 
stigmata” as outlined in the 2012 IAP guidelines.
Th e updated 2012 IAP and 2015 AGA guidelines 
recommend surveillance for suspected low-risk BD-IPMN 
using EUS, CT or MRI at intervals ranging between 3 months 
to 2 years depending upon cyst features. Whether the risk of 
developing pancreatic malignancy is suffi  ciently low to support 
non-operative management in benign-appearing lesions 
remains uncertain given the lack of natural history data of BD-
IPMN. Studies that have looked at long-term outcomes of BD-
IPMN (i.e. ≥1 year of follow up) have shown good outcomes for 
those patients entered into surveillance programs. However, 
small cohort sizes and/or confi nement to single institutions 
limit generalizability of these studies [5,28-34]. In this study, 
over 600  patients at 4 referral centers were followed long-
term for up to 12  years and showed that most patients did 
well. Th is is especially true in the LRG, where only one patient 
developed pancreatic cancer aft er 6 years of follow up. Th us, 
patients with presumptive BD-IPMN that appear benign on 
EUS examination and lack Fukuoka criteria can be observed 
with little risk of developing cancer. However, the safety of 
surveillance is less clear in those with Fukuoka “worrisome 
features” where risk of malignancy is increased.
Establishing the malignant potential of a given cyst using 
the Fukuoka criteria or AGA guidelines requires discerning 
the presumed cyst type. Based upon the histology of surgically 
resected cysts approximately one quarter of presumptive BD-
IPMN were likely benign, non-mucinous cyst types (Table 4). 
Consequently, the calculated risk of pancreatic malignancy 
in the HRG of this study would likely be slightly higher if 
benign lesions had been excluded from analyses. Improved 
accuracy of cyst diagnosis would have also reduced the 
number of unnecessary surgeries. Selective use of EUS-FNA 
sampling of cyst fl uid for CEA and amylase has been shown 
to aid in the diagnosis cyst type with an accuracy ranging 
between 62 and 79% [35-37]. However, cyst fl uid analysis 
requires specialized training, incurs additional expenses for 
consumables and cytopathology and may carry up to 5% rate 
of complication [38]. In the current study, less than half of 
the resected mucinous cysts in which preoperative CEA was 
available was concentration above the threshold of 192 ng/mL. 
Th ough the study was not designed to evaluate the impact of 
cyst fl uid CEA on patient management these results suggest 
limited eff ectiveness of CEA in discerning mucinous cysts.
Th ough the elderly are disproportionately aff ected by 
pancreatic cysts, younger patients are more apt to undergo 
surgical resection for these cystic lesions. In studies that have 
included both operatively managed and surveillance, including 
this study, patients who undergo resection tend to be between 
Figure 2 Cumulative incidence of pancreatic cancer in the highest (upper red line) and lowest (lower black line) risk groups
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Table 5 Frequency of pancreatic cancer diagnosed within 3 months, 
3 to 12 month, and aft er 12 months following index endoscopic 
ultrasound in the highest-risk and lowest-risk groups
<3 m* 3-12 m >12 m Total
Highest-risk group
“High-risk stigmata” 31 2 3 36
“Worrisome features” 9 6 8 23
Lowest-risk group 0 0 1 1
*Diagnosis based upon cytology obtained during endoscopic ultrasound-fine 
needle aspiration or the pathology of surgically resected tissue
m, months
Low-risk pancreatic cysts and Fukuoka criteria  493
Annals of Gastroenterology 28
6 and 10 years younger [10,39,40]. Th is suggests that patient 
age and preferences may have been decisive factors and that 
the elderly are less likely to undergo risky surgical procedures.
Th ere are several limitations of this study. Th is is a 
retrospective cohort study of patients referred for EUS 
evaluation of pancreatic cystic lesions using data obtained 
from review of medical records and EUS reports. Cysts 
were classifi ed as suspected BD-IPMN based upon available 
clinical and morphologic features rather than EUS FNA cyst 
fl uid analysis, cytology or histology of resected tissue, and 
therefore it is possible that some cysts were not BD-IPMN but 
possibly macrocystic serous cystadenomas, retention cysts, or 
other benign etiologies. Th ough cytology, histology or clear 
cross-sectional imaging confi rmed most cases of pancreatic 
cancer a minority were based upon interview of close family 
members. Also, distinction was not made between malignancy 
occurring within IPMN and those arising elsewhere in the 
pancreas (i.e.  concomitant cancer). Patients were medically 
and surgically managed at the discretion of each endoscopist 
and other members of their healthcare team in conjunction 
with patient preference rather than by a standard protocol. 
Although patients were followed for an average 4  years aft er 
initial EUS examination allowing for Kaplan-Meier statistics to 
7 years, longer duration of follow up is needed to understand 
better the natural history of BD-IPMN. Follow-up information 
on changes in cyst characteristics over time, such as cyst size 
and development of Fukuoka criteria, was also not evaluated. 
Fukuoka criteria were not systematically incorporated into 
report format, thus if criteria not mentioned it was assumed 
to be absent. Another limitation is that the low rate of cancer 
development in the low-risk group could be due to the 
inclusion of cysts that were not BD-IPMN (i.e.  macrocystic 
serous cystadenomas or retention cysts).
Th e strengths of this study lend to its eff ective representation 
of real-life patient care at four separate institutions; thus 
results are clinically useful and generalizable. Referral bias 
was minimized since the cohort included patients from a 
large, integrated healthcare system and a tertiary academic 
referral center. Cysts types were classifi ed by clinical and EUS 
information that can be easily attained by most clinicians during 
diagnostic workup of incidentally discovered pancreatic cystic 
lesion. Th e large group of non-operatively managed patients 
and long-term follow up also allowed for a detailed description 
of the natural history of presumptive BD-IPMN.
In summary, this study supports the use of the Fukuoka “high-
risk stigmata” and “worrisome features” criteria in stratifying the 
malignant potential of cysts consistent with BD-IPMN. Th is 
study supports surveillance of benign appearing cysts that lack 
Fukuoka criteria, or high-risk features as identifi ed by AGA 
2015 guidelines because they pose little to no risk to the patient. 
Most patients who develop pancreatic cancer in BD-IPMN have 
at least one Fukuoka criterion and are most oft en diagnosed 
with pancreatic cancer within a year of the cyst being detected. 
However, patients not diagnosed with cancer within the fi rst 
year, continue to be at risk for developing pancreatic cancer over 
time, even in those who initially did not have Fukuoka criteria at 
the time of initial EUS. Th us surveillance should be continued in 
patients with presumptive BD-IPMN.
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